Dexmedetomidine for Catheter-related Bladder Discomfort

Study Overview
=================
Brief Summary
-----------------
To evaluate the efficacy of dexmedetomidine for the prevention of catheter-related bladder discomfort

Detailed Description
-----------------
After transurethral bladder resection, large-sized foley catheter have been used for drainage of urine and residual blood. Because of urinary catheterization, patients usually experiences catheter-related bladder discomfort defined as a burning sensation with an urge to void or discomfort in the supra-pubic region caused by catheter- related bladder irritation. Dexmedetomidine is an alpha-2 antagonist and used as an analgesic agent. The investigators try to evaluate The efficacy of dexmedetomidine for the treatment of catheter-related bladder discomfort

Official Title
-----------------
Efficacy of Dexmedetomidine for the Therapy of Catheter-related Bladder Discomfort

Conditions
-----------------
Pain, Blood Pressure, Nausea, Vomiting, Arrhythmia

Intervention / Treatment
-----------------
* Drug: Dex infusion
* Drug: NS infusion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients scheduled for transurethral bladder resection ASA I-III Exclusion Criteria: Patient who disagrees to participate this investigation Patient with severe cardiovascular disease Patient with small-sized foley catheter (less than 18 Fr.) Patinets with any urinary tract obstructions Patient with hyperactive or neurogenic bladder Patients with chronic renal failure Patient with morbidly obese Patients with neurogenic disorder Patient with medications for chronic pain

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Placebo group<br>NS infusion will be done during surgery. | Drug: NS infusion<br>* Normal saline will be infused during surgery<br>|
| Experimental: Dex group<br>DEX infusion will be done during surgery. | Drug: Dex infusion<br>* Dexmedetomidine will be injected (1 mcg/kg for 10 minutes and afterward 0.3 mcg/kg/hr)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The number of patients with catheter-related bladder discomfort | catheter-related bladder discomfort at postoperative 1 hour was evaluated as none, mild, moderate, severe. The number of patients with mild, moderate, severe discomfort will be calculated and compared between groups. | at postoperative 1 hour | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Catheter-related bladder discomfort | Catheter-related bladder discomfort will be evaluated as none, mild, moderate, severe at postoperative 0, 1, 6, 24 hours. | at postoperative 0, 1, 6, 24 hours | 
| Pain at suprapubic area | Pain at suprapubic area will be evaluated using NRS (0:none, 100:worst imaginable) at postoperative 0, 1, 6, 24 hours | at postoperative 0, 1, 6, 24 hours |